Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use
View Patent ↗Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in modulating intracellular calcium.
1. A composition for an intracellular calcium modulator assay, comprising: a recombinant cell that expresses an exogenous polynucleotide encoding a polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence of a human or rodent Stromal Interacting Molecule (STIM) 1 protein of SEQ ID NO:4, 10, or 52, wherein the recombinant protein retains human or rodent STIM 1 intracellular calcium-modulating activity; and an exogenous agent that provides for reduction of calcium levels in an intracellular store, wherein the exogenous agent that provides for reduction of calcium levels in an intracellular store is in contact with the recombinant cell, and is selected from the group consisting of: an antagonist of the endoplasmic reticulum calcium ATPase pump, an agonist of a G-protein coupled receptor that activates phospholipase C, IP3, phospholipase C, an agonist of a ryanodine receptor, an ionophore, N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN), 1,2-bis(2-amino-phenoxy)ethane-N,N,N,N′-tetraacetic acid (BAPTA) and ethylene glycol tetraacetic acid (EGTA).
2. The composition of claim 1 , wherein the recombinant polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:10.
3. The composition of claim 1 , wherein the recombinant polypeptide comprises an amino acid sequence at least 95% identical the amino acid sequence of SEQ ID NO:4.
4. The composition of claim 3 , wherein the recombinant polypeptide comprises the amino acid sequence of SEQ ID NO:4, 10 or 52.
5. The composition of claim 1 , wherein the exogenous agent that provides for reduction of calcium levels in an intracellular store is selected from among IP3, phospholipase C, thapsigargin, cyclic ADP ribose, ionomycin, caffeine, ryanodine, cyclopiazonic acid, N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN), di-tert-butyl-hydroquinone, histamine, muscarine, carbachol, substance P, bradykinin, serotonin, uridine triphosphate (UTP) and glutamate.
6. The composition of claim 1 , wherein the recombinant cell is a human recombinant cell, a mouse recombinant cell, a rodent recombinant cell, an insect recombinant cell, or a xenopus recombinant cell.
7. The composition of claim 1 , wherein the recombinant ceil is a mammalian recombinant cell.
8. The composition of claim 1 , wherein the recombinant cell is a human recombinant cell.
9. The composition of claim 1 , wherein the exogenous agent that provides for reduction of calcium levels in an intracellular store comprises thapsigargin, caffeine, or ryanodine.
10. The composition of claim 5 , wherein the exogenous agent that provides for reduction of calcium levels in an intracellular store comprises thapsigargin.
11. The composition of claim 5 , wherein the exogenous agent that provides for reduction of calcium levels in an intracellular store comprises ryanodine.
12. The composition of claim 1 , wherein the recombinant polypeptide comprises an amino acid sequence at least 95% identical the amino acid sequence of SEQ ID NO: 52.
13. A composition comprising:
(i) a recombinant cell that expresses an exogenous polynucleotide encoding a polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence of a human or rodent stromal interacting molecule (STIM) 1 protein of SEQ ID NO:4, 10, or 52, wherein the recombinant protein retains human or rodent STIM 1 intracellular calcium-modulating activity;
(ii) an exogenous agent that provides for reduction of calcium levels in an intracellular store, wherein the exogenous agent is selected from the group consisting of: an antagonist of the endoplasmic reticulum calcium ATPase pump, an agonist of a G-protein coupled receptor that activates phospholipase C, IP3, phospholipase C, an agonist of a ryanodine receptor, an ionophore, N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN), 1,2-bis(2-amino-phenoxy)ethane-N,N,N,N′-tetraacetic acid (BAPTA) and ethylene glycol tetraacetic acid (EGTA); and
(iii) a test agent to be assayed for its ability to modulate intracellular calcium in the recombinant cell.